NDAINHALATIONGAS
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for vocal cord dysfunction, hypertrophic scar, actinic keratosis and 11 more indications. First approved in 2019.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARBON DIOXIDE, USP is an inhaled gas product approved as a radiographic contrast agent with a mechanism of action in X-ray contrast activity. The product is indicated for a diverse range of conditions including vocal cord dysfunction, hypertrophic scars, actinic keratosis, migraine, nasal congestion, neonatal encephalopathy, ARDS, hypoxia, and resuscitation. It represents a novel application of CO₂ gas as a therapeutic modality across multiple clinical domains.
Peak
Peak lifecycle status suggests mature commercial operations, but lack of publicly available spending data indicates either a niche market or limited commercial penetration requiring market development efforts.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.